Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MSC-1
AZD0171 · 2 trials · 5 indications
The safety and tolerability of study intervention (AZD0171, durvalumab, and standard-of-care chemotherapy) was assessed. The grading scales found in the revised National Cancer Institute CTCAE latest version was utilized for all events with an assigned CTCAE grading. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL); Grade 4: Life-threatening, urgent intervention required; Grade 5: Death related to AE.
Percentage of participants alive at 12 months after initiation of study intervention per Kaplan- Meier estimate of OS at 12 months.
Assessment of frequency \& severity of adverse events
Determine objective response rate (ORR)
| Arm | Type | Description |
|---|---|---|
| AZD0171 + Durvalumab + chemotherapy | EXPERIMENTAL | Participants will receive AZD0171 (intravenous \[IV\]) along with durvalumab (IV) in combination with standard-of-care chemotherapy IV (gemcitabine and nab-paclitaxel). |
| Dose Escalation | EXPERIMENTAL | Multiple dose levels of MSC-1 treatment once every 3 weeks |
| Dose Expansion | EXPERIMENTAL | MSC-1 treatment at the recommended Phase 2 dose once every 3 weeks |
| Name | Type | Description |
|---|---|---|
| AZD0171 | DRUG | AZD0171 |
| Durvalumab | DRUG | Durvalumab |
| Gemcitabine | DRUG | Chemotherapy (Standard-of-Care) |
| Nab-paclitaxel | DRUG | Chemotherapy (Standard-of-Care) |
| MSC-1 | BIOLOGICAL | humanized monoclonal antibody for intravenous administration |
Inclusion Criteria: * Eastern Cooperative Oncology Group performance status of 0 or 1 at screening/enrolment * Must have a Gustave Roussy Immune Score of 0 or 1 * Participants diagnosed with histologically confirmed metastatic pancreatic adenocarcinoma * Participants must have at least 1 measurable...
AZD0171 is an investigational small molecule being studied for the treatment of locally advanced or metastatic solid tumours. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
AZD0171 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN.
AZD0171 is currently in Phase 2 clinical development. It is an investigational drug and has not yet received regulatory approval for any indication.
AZD0171 is being evaluated in a Phase 2 clinical trial with the identifier NCT04999969. This trial is active but not recruiting participants and is studying the drug in combination with durvalumab and chemotherapy in patients with locally advanced or metastatic solid tumours.
No, AZD0171 is not the same as durvalumab. AZD0171 is a small molecule being studied in combination with durvalumab, which is a separate immunotherapy agent, in a clinical trial for solid tumours.